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Modification of the association between paroxetine 
serum concentration and SERT-occupancy by ABCB1 
(P-glycoprotein) polymorphisms in major depressive disorder
Mirjam Simoonsa,b,c, Hans Muldera,d, Jerôme T.Y. Appeldoorna,  
Arne J. Risseladaa, Aart H. Schenee, Ron H.N. van Schaikf,  
Eric N. van Roonc,g and Eric G. Ruhéb,e,h       
Background Selective serotonin reuptake inhibitors 
(SSRIs) exert substantial variability in effectiveness in 
patients with major depressive disorder (MDD), with up 
to 50–60% not achieving adequate response. Elucidating 
pharmacokinetic factors that explain this variability is 
important to increase treatment effectiveness. 
Objectives To examine potential modification of the 
relationship between paroxetine serum concentration 
(PSC) and serotonin transporter (SERT)-occupancy by 
single nucleotide polymorphisms (SNPs) of the ABCB1 
gene, coding for the P-glycoprotein (P-gp) pump, in MDD 
patients. To investigate the relationship between ABCB1 
SNPs and clinical response.
Methods Patients had MDD and received paroxetine 
20 mg/day. We measured PSC after 6 weeks. We quantified 
SERT-occupancy with SPECT imaging (n = 38) and measured 
17-item Hamilton Depression Rating Scale (HDRS
17
)-scores 
at baseline and after 6 weeks (n = 81). We genotyped ABCB1 
at rs1045642 [3435C>T], rs1128503 [1236C>T], rs2032582 
[2677G>T/A] and rs2235040 [2505G>A]. For our primary 
aim, we modeled mean SERT-occupancy in an E
max
 nonlinear 
regression model with PSC and assessed whether the 
model improved by genetic subgrouping. For our secondary 
aim, we used multivariate linear regression analysis.
Results The rs1128503 and rs2032582 SNPs modified 
the relationship between PSC and SERT-occupancy in 
both our intention-to-treat and sensitivity analyses at the 
carriership level. However, we could not detect significant 
differences in clinical response between any of the genetic 
subgroups.
Conclusion Pharmacokinetic influences of the ABCB1 
rs1128503 and rs2032582 represent a potentially relevant 
pharmacogenetic mechanism to consider when evaluating 
paroxetine efficacy. Future studies are needed to support 
the role of ABCB1 genotyping for individualizing SSRI 
pharmacotherapy. Psychiatr Genet 30: 19–29 Copyright © 
2019 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Selective serotonin reuptake inhibitors (SSRIs) are 
among the most frequently prescribed classes of drugs 
for treatment of major depressive disorder (MDD) (Chen 
et al., 2008; Noordam et al., 2015; Stephenson et al., 2013). 
They exert their antidepressant effect by occupying the 
serotonin transporter (SERT), thereby blocking presyn-
aptic reuptake of serotonin (Rominger et al., 2015; Yeh et 
al., 2015). Unfortunately, SSRIs show substantial variabil-
ity in their effectiveness. Up to 50–60% of MDD patients 
do not achieve a clinically relevant response (Fava, 2003; 
Trivedi et al., 2006). Although many factors such as age, 
sex, body weight, genetics and comedication are related 
to this variability (Dechant and Clissold, 1991; Sindrup et 
al., 1992; Bagby et al., 2002; Kugaya et al., 2004; Serretti 
et al., 2005; Feng et al., 2006; Kato et al., 2006; Domschke 
et al., 2014), more specifically pharmacodynamic and 
pharmacokinetic factors may be important to under-
stand variations in SSRI response rates. If such factors 
are elucidated, treatment with SSRIs may be optimized 
by personalizing drug choices and dosing. In this study, 
we focus on the pharmacokinetic mechanisms of MDD 
treatment with the SSRI paroxetine.
Systemic and brain availability of paroxetine is influenced 
by the permeability glycoprotein (P-gp) efflux pump as 
reported in in-vitro and in-vivo studies (O’Brien et al., 
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2012). P-gp is located in, among others, the blood–brain 
barrier and protects the brain against potentially toxic sub-
stances by clearing its substrates out of the brain at the 
blood–brain barrier. In fact, P-gp is the primary drug efflux 
mechanism, and thus responsible for drug concentra-
tions within the brain (Cordon-Cardo et al., 1989). P-gp is 
encoded by the ATP binding cassette subfamily B mem-
ber 1 (ABCB1; or MDR1) gene (Linnet and Ejsing, 2008).
Research on the influence of ABCB1 polymorphisms on 
treatment outcomes during SSRI treatment has yielded 
mixed results (Kato et al., 2006; Gex-Fabry et al., 2008; 
Kato et al., 2008; Mihaljevic Peles et al., 2008; Uhr et al., 
2008; Menu et al., 2010; Sarginson et al., 2010; Kato et al., 
2015; Ray et al., 2015). Two recent meta-analyses found 
no associations between six ABCB1 SNPs and SSRI treat-
ment outcomes (Niitsu et al., 2013; Breitenstein et al., 
2015), except for rs2032582 in one meta-analysis: patients 
with GT and TT genotypes showed better remission 
rates than those with GG (Niitsu et al., 2013). Of note, 
one out of three unique rs2032582 studies investigated 
paroxetine specifically (Kato et al., 2008). Furthermore, 
the rs2235040 variant A-allele has been associated with 
shorter time to remission in paroxetine-treated patients 
(Sarginson et al., 2010). The rs1045642C-rs2032582G–
rs1128503T-haplotype has been associated with poor 
paroxetine response, while other haplotypes showed no 
association with response (Kato et al., 2008). Therefore, 
no definite conclusions can be drawn concerning the 
involvement of ABCB1 polymorphisms in the treatment 
effects of SSRIs in general or paroxetine in particular.
At a pharmacokinetic level, several studies on involve-
ment of P-gp in paroxetine treatment have been per-
formed using paroxetine serum concentration (PSC) 
(Yasui-Furukori et al., 2007; Gex-Fabry et al., 2008; 
O’Brien et al., 2012). Unfortunately, PSC cannot be used 
to predict clinical response and as such is not a measure 
for treatment outcome. Furthermore, investigation of the 
relationship between P-gp and PSC might not address 
the expected differences in intracerebral levels of parox-
etine as determined by P-gp, for which SERT-occupancy 
is a better measure (Ruhé et al., 2013). SERT-occupancy 
can be visualized and calculated in vivo using radioligands 
and PET or single-photon emission computed tomog-
raphy (SPECT) imaging. In general, SERT-occupancy 
plateaus at low SSRI serum levels, both in healthy and 
MDD subjects (Meyer et al., 2004; Ruhé et al., 2013). 
It has been suggested that a SERT-occupancy level of 
>80% is necessary for clinical response (Meyer et al., 2001; 
Suhara et al., 2003; Meyer et al., 2004), although response 
might also occur at lower levels (Ruhé et al., 2009a). 
Differences in curves describing serum concentrations 
and SERT-occupancy for different ABCB1 polymor-
phisms might therefore explain the variability between 
SSRI serum concentrations and SERT-occupancy on the 
one hand and clinical response on the other hand. To the 
best of our knowledge, the association between PSC and 
SERT-occupancy stratified by ABCB1 polymorphisms 
has not been investigated before.
We hypothesized that the ABCB1 polymorphisms with 
lower P-gp expression or activity or an association with 
favorable treatment outcomes  or two or all of these 
three phenotypic presentations, would (1) also influence 
the nonlinear relationship between PSC and SERT-
occupancy in the midbrain, with higher SERT-occupancy 
in these variant allele groups because of higher paroxe-
tine concentrations in the brain and (2) be associated with 
higher response rates during paroxetine use (Ruhé et al., 
2009a; Sarginson et al., 2010; Brambila-Tapia, 2013).
Our primary aim was to evaluate whether the three 
most studied ABCB1 SNPs (rs1045642 [3435C>T], 
rs1128503 [1236C>T] and rs2032582 [2677G>T/A]) 
and the aforementioned rs2235040 [2505G>A] modified 
the relationship between PSC and SERT-occupancy in 
paroxetine-treated MDD patients. As a secondary aim, 
we investigated the relationship of these SNPs and the 
rs1045642C-rs2032582G–rs1128503T-haplotype with 
clinical response in a larger sample of paroxetine-treated 
MDD patients.
Methods
Design, setting and study population
Data and DNA-samples in this study were from the first six 
weeks of the ‘Dose-Escalation Legitimate? Pharmacology 
and Imaging studies in depression’ (DELPHI)-trial and 
the nested neuroimaging substudy DELPHI-SPECT 
(ISRCTN register no. ISRCTN44111488) described 
earlier (Ruhé et al., 2009a,b). We previously reported 
on modification by SERT-polymorphisms of the associ-
ation between SERT-occupancy and clinical response 
in the same sample (Ruhé et al., 2009a). The study was 
approved by the Academic Medical Centre (AMC) med-
ical ethical committee and all participants provided writ-
ten informed consent. In short, patients aged 17–70 years 
[25–55 years for the SPECT-sample to reduce variability 
in SERT-measurements by age (van Dyck et al., 2000)] 
diagnosed with a major depressive disorder and drug-
free (SPECT-sample; washout >5 half-lives of previous 
treatments if any) or who had undergone no more than 
one antidepressant treatment (other than paroxetine) 
for the present MDD-episode were eligible for the 
study. Patients were treated with paroxetine 20 mg/day 
for six weeks; only short-acting benzodiazepines were 
allowed as incidental comedication. More detailed infor-
mation about the design, setting and study population 
is described elsewhere (Ruhé et al., 2009a,b) and can 
be found in the Supplemental Methods, Supplemental 
Digital Content 1, http://links.lww.com/PG/A230.
Primary outcome: serotonin transporter-occupancy
Primary outcome was the SERT-occupancy by paroxe-
tine in the midbrain. We a priori chose to use only the 
midbrain SPECT-data, as midbrain SERT-occupancy 
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had previously been shown to be most reliably asso-
ciated with PSC (Ruhé et al., 2009a), and to avoid the 
need for power-lowering corrections for multiple test-
ing in our limited SPECT sample. SPECT imaging for 
in-vivo assessment of SERT availability was performed 
at study-entry and after six weeks of paroxetine treat-
ment between 2 and 10 pm according to previously 
described procedures (de Win et al., 2005). All scans were 
made 230 ± 18 (SD) minutes after intravenous injection 
of 100 MBq [123I]methyl 3ß-(4-iodophenyl) tropane-2 ß 
–carboxylate ([123I] β-CIT), when the radioligand is at 
equilibrium for SERT binding in brain areas expressing 
high densities of SERTs, such as the midbrain (Pirker 
et al., 2000). We measured the SERT-occupancy in the 
midbrain as a proxy for cortical SERT-occupancy. The 
definitions of the regions of interest for midbrain and cer-
ebellum (reference) has been described previously (de 
Win et al., 2005; Ruhé et al., 2009a,b). Using activity in 
the cerebellum as indicator of nondisplaceable activity 
(nonspecific binding and free radioactivity) in calculat-
ing the nondisplaceable binding potential (BP
ND
) of the 
radioligand to SERT as described previously (Ruhé et al., 
2009a), we calculated SERT-occupancy at 6 weeks rela-
tive to the untreated SERT BP
ND
 (study-entry) as 
OCC
BP BP
BP6weeks
NDstudy-entry ND6weeks
NDstudy-entry
=
−( )�
Secondary outcomes: 17-item Hamilton Depression 
Rating Scale score
Secondary clinical outcomes were the absolute decrease 
in 17-item Hamilton Depression Rating Scale (HDRS
17
) 
score (Hamilton, 1960), and the proportion of patients 
achieving response (≥50% decrease in HDRS
17
-score). 
The HDRS
17
 is a well validated instrument to measure 
the severity of MDD (Hamilton, 1960). The HDRS
17
 was 
administered at study-entry and after six weeks of parox-
etine treatment.
Permeability glycoprotein-genotyping procedures and 
analysis
Genomic DNA was isolated out of blood using a fil-
ter-based method (QIAamp DNA Mini Kit; Qiagen 
Ltd, Manchester,  UK). ABCB1 genetic polymorphisms 
rs1045642 [3435C>T], rs1128503 [1236C>T], rs2032582 
[2677G>T/A] and rs2235040 [2505G>A] were deter-
mined with allelic discrimination on an ABI 7500 Thermal 
Cycler using validated Drug Metabolizing Enzyme assays 
C-7586657-20 (C3435C>T), C-7586662-10 (1236C>T), 
C-11711720C-30 and C-11711720D-40 (2677G>T/A) and 
C-15951386-20 (2505G>A) (ThermoFisher Scientific, 
Waltham, Massachusetts, USA).
Paroxetine serum concentrations
Blood for paroxetine trough serum concentration (PSC; 
therapeutic range 10–75 μg/L) was collected after six 
weeks of treatment, immediately before SPECT scan-
ning. For subjects who did not participate in the SPECT 
study, blood for PSC could only be obtained in subjects 
treated at the AMC (n = 15), and was collected immedi-
ately after the study visit at week 6. Storage and meas-
urement of PSC have been described before (Ruhé et al., 
2009a).
Statistical analysis
We performed descriptive and statistical analyses using 
IBM SPSS (version 24 for Windows; IBM Corp., Armonk, 
New York, USA) and GraphPad Prism (version 5.0 for 
Windows; GraphPad Software Inc., La Jolla, California, 
USA). For comparison of differences between groups 
in dichotomous and categorical variables, we used Chi 
square tests or Fisher’s exact tests as appropriate. For 
comparison of differences in continuous variables, we 
used independent t-tests or ANOVAs. We report medi-
ans and used Mann–Whitney U tests for non-normally 
distributed continuous variables. Differences were con-
sidered statistically significant when P <0.05.
To investigate the potential modification of the PSC-
SERT-occupancy relationship by ABCB1 polymor-
phisms, we modeled SERT-occupancy after six weeks 
(OCC
6 weeks
) in an E
max
 model as OCC
6weeks
=aPSC(b+PSC), 
in which a represents maximal SERT-occupancy in 
the model (OCC
max
) and b the PSC with 50% SERT-
occupancy (EC
50
) (Meyer et al., 2001; Kent et al., 2002; 
Suhara et al., 2003; Catafau et al., 2006; Takano et al., 
2006). We calculated a and b by fitting a nonlinear 
regression model that minimizes the sum of squares of 
the residuals in GraphPad Prism and SPSS. To assess 
whether PSC-SERT-occupancy curves improved by 
subgrouping (genetic subgroups), we fitted one curve, 
two curves (carriership) or three curves (genotypes) and 
determined whether the separate curves decreased the 
Akaike Information Criterion (AIC; lower is better), 
which expresses the −2 log-likelihood of the (nested) 
model penalized for the number of independent varia-
bles in the model.
To investigate the relationship between ABCB1 poly-
morphisms (genotype and carrier groups) and clinical 
response, we performed multivariate linear regression 
analysis for the absolute decrease in HDRS
17
-score cor-
rected for baseline HDRS
17
-score (analysis of covari-
ance) and multivariate logistic regression analysis for 
the number of responders (patients with ≥50% decrease 
in HDRS
17
-score). We investigated the data for poten-
tial confounding by age, sex and PSC. These variables 
were included in the models if they were univariately 
associated with the outcome (using analysis of covari-
ance) at a significance level of P <0.20 (Maldonado and 
Greenland, 1993).
All data were analyzed on an intention-to-treat basis. 
One responder and four nonresponders were potentially 
nonadherent [PSC < 5 μg/L, or reported to not have taken 
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most or all of the dosages or answered ‘yes’ to three or four 
questions of the Morisky scale after 6 weeks (Morisky et 
al., 1986)]. We performed a sensitivity analysis to investi-
gate the influence of nonadherent cases on both analyses 
(SERT-occupancy and clinical response). We performed 
another sensitivity analysis to investigate the influence 
of the non-Caucasian subjects on both analyses (SERT-
occupancy and clinical response).
Results
Participants
Of 278 patients referred for assessment of eligibility, 
107 started treatment with paroxetine 20 mg/day in 
the DELPHI-study. Eighty-one patients finished the 
six weeks of paroxetine treatment and the HDRS
17
-
measurements at baseline and after 6 weeks. Of these, 
46 patients with analyzable baseline scans of the mid-
brain were included in the current SPECT substudy. 
For the analyses of the PSC-SERT-occupancy models, 
three patients were excluded, because the OCC
6 weeks
 in 
the midbrain could not be calculated due to unanalyz-
able (repeated) scans. Moreover, five patients dropped 
out due to adverse effects, leaving a sample size of 38 
SPECT-patients.
At study-entry, no significant clinical, demographic, 
imaging or genetic differences were found at baseline 
between responders (n = 25) and nonresponders (n = 56) 
in the total study population except for alcohol use (≤/>7 
units/week P = 0.02, all other P ≥ 0.08; Table 1). No signifi-
cant differences were found between the SPECT-sample 
(n = 38) and other patients in the total study population 
Table 1 Characteristics of the total study population (n = 81) stratified by response after 6 weeks of paroxetine 20 mg/day
Respondersa,b (n = 25) Nonrespondersa,b (n = 56) P valuec
Age at baseline (years) 44.8  ±  1.8 43.0  ±  1.3 0.43
Sex (female) 17 (68.0) 37 (66.1) 0.87
Ethnicity   0.73
 Caucasian 14 (56.0) 34 (60.7)  
 Surinamese-Creole 2 (8.0) 4 (7.1)  
 Surinamese-Hindu 2 (8.0) 3 (5.4)  
 Antillian-Aruban 2 (8.0) 6 (10.7)  
 Other 5 (20.0) 9 (16.1)  
Level of education   0.72
 Low 6 (24.0) 14 (25.5)  
 Middle 13 (52.0) 32 (58.2)  
 High 6 (24.0) 9 (16.4)  
Current smoker 10 (43.5) 28 (50.0) 0.60
Alcohol use   0.02
 ≤7 units/week 16 (66.7) 51 (91.1)  
 >7 units/week 8 (33.3) 5 (8.9)  
HDRS
17
 at baseline 22.9  ±  0.7 24.8  ±  0.6 0.08
First episode 12 (48.0) 35 (62.5) 0.22
No of episodes [median (range)] 2 (1–10) 1 (1–10) 0.16
Melancholic 17 (89.5) 38 (88.4) 1.00
Duration of episode   0.55
 <5 months 7 (28.0) 13 (23.6)  
 5 months–2 years 14 (56.0) 37 (67.3)  
 ≥2 years 4 (16.0) 5 (9.1)  
Psychiatric comorbidity 12 (50.0) 18 (32.1) 0.13
Drug naïve 14 (62.5) 38 (67.9) 0.64
Used psychotropic drugs in current episode 4 (16.7) 7 (12.5) 0.73
SERT-availability midbrain at baseline (n = 38) 0.60  ±  0.09 (n = 8) 0.61  ±  0.03 (n = 30) 0.83
P-gp genotype rs1045642   0.36
 CC 5 (20.0) 17 (30.4)  
 CT 9 (36.0) 23 (41.1)  
 TT 11 (44.0) 16 (28.6)  
P-gp genotype rs1128503   0.83
 CC 7 (28.0) 18 (32.1)  
 CT 13 (52.0) 25 (44.6)  
 TT 5 (20.0) 13 (23.2)  
P-gp genotype rs2032582   0.92
 GG 11 (44.0) 22 (39.3)  
 GT or GA 9 (36.0) 22 (39.3)  
 AA or TT or TA 5 (20.0) 12 (21.4)  
P-gp genotype rs2235040   1.00
 GG 20 (80.0) 43 (76.8)  
 GA 4 (16.0) 9 (16.1)  
 AA 1 (4.0) 4 (7.1)  
rs1045642 C -rs2032582 G- rs1128503   0.67
 T-haplotype
  Present 9 (36.0) 23 (41.1)  
HDRS
17
, Hamilton Depression Rating Scale; SERT, serotonin transporter.
aData are given as number (percentage) or mean  ±  SEM unless stated otherwise. 
bResponders defined as patients with ≥50% decrease in baseline HDRS
17
-score.
cP values <0.05 are shown in bold.
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(n = 43) (all P ≥ 0.05; Supplemental Table 1, Supplemental 
Digital Content 1, http://links.lww.com/PG/A230).
Difference in paroxetine serum concentration, 
nondisplaceable binding potential and serotonin 
transporter-occupancy by ABCB1 genotype after 
6 weeks of treatment
We found no differences in mean PSC, BP
ND
 or SERT-
occupancy between the various genotype groups in the 
SPECT-sample (n = 38, all P > 0.12; Supplemental Table 
2/inlays in Supplemental Fig. 1, Supplemental Digital 
Content, Supplemental Digital Content 1, http://links.lww.
com/PG/A230) or between the carriership groups for the 
four SNPs (Table 2/inlays in Fig. 1), except for rs2235040: 
carriers of the variant A-allele (n = 10) had lower PSC than 
noncarriers (n = 28; P < 0.01, all other P > 0.06).
Relationship between serotonin transporter-occupancy 
and paroxetine serum concentration by ABCB1 
genotype
The PSC-SERT-occupancy curve in the midbrain was 
curvilinear (F
2,36 
= 263.8, P < 0.0001; AIC = −120.0; see 
Supplemental Fig. 1, Supplemental Digital Content 
1, http://links.lww.com/PG/A230). The EC
50
 and E
max
 
values for the unstratified and all stratified models are 
shown in Supplemental Table 3, Supplemental Digital 
Content 1, http://links.lww.com/PG/A230. The nonlinear 
regression models were significant throughout all strati-
fications for genotype (all F
6,32 
> 44.1; all P < 0.0001) and 
carriership (all F
4,34
 > 90.4; all P < 0.0001). Stratification 
of the PSC-SERT-occupancy curve by ABCB1 genotype 
did not indicate an improvement of the model for any 
of the four SNPs under study, as the models with three 
curves per SNP (Supplemental Fig. 1, Supplemental 
Digital Content 1, http://links.lww.com/PG/A230) 
resulted in higher AICs than the model with one curve 
fitting the data (AIC increase 27.4 for rs1045642, 19.5 
for rs1128503, 14.8 for rs2032582 and 19.5 for rs2235040, 
respectively).
When we analyzed the data for ABCB1 genotype carri-
ership of the wildtype allele rs1128503 (AIC = −121.8) 
and rs2032582 (AIC = −123.7) and the variant allele for 
rs1045642 (AIC = −120.2) and rs2235040 (AIC = −104.9; 
Fig. 1), we observed decreases in AIC when fitting two 
curves for rs1128503 (AIC decrease 1.8) and rs2032582 
(AIC decrease 3.8) and rs1045642 (AIC decrease 0.2), 
indicating improved fit of the models for these SNPs, but 
not for rs2235040 (AIC increase 15.0).
In our first sensitivity analysis, leaving out nonadherent 
cases, again no better fit of the data was found when 
stratifying for ABCB1 genotypes (n = 33; AIC for the 
unstratified model = −101.8, all AIC increases > 0.6; data 
not shown). However, stratification for ABCB1 carriership 
improved fitting for rs1128503, rs2032582 and rs2235040 
(AIC decreases 1.9, 4.3 and 1.6, respectively) but dete-
riorated the model fit for rs1045642 (AIC increase 1.4; 
Supplemental Table 4, Supplemental Digital Content 1, 
http://links.lww.com/PG/A230).
Our second sensitivity analysis, leaving out non- 
Caucasian cases, did not change the results compared 
with the original intention-to-treat analysis: stratification 
for genotype did not improve the model for any of the 
four SNPs (n = 25; AIC for the unstratified model = −78.2, 
all AIC increases >0.6 compared to the unstratified model 
Table 2 Mean paroxetine serum concentration (μg/L), mean baseline nonspecific binding ratio and mean serotonin transporter-occu-
pancy (%) by ABCB1 single nucleotide polymorphism allele carriership in the single-photon emission computed tomography-sample 
(n = 38) after 6 weeks of paroxetine 20 mg/day
A. Mean PSC (μg/L) by ABCB1 SNP allele carriershipa
SNP Carrier (genotype; n) Noncarrier (genotype; n) P valueb
rs1045642 (variant allele) 38.9 ± 6.7 (CT/TT; n = 25) 51.3 ± 10.1 (CC; n = 13) 0.30
rs1128503 (wildtype allele) 45.0 ± 7.3 (CC/CT; n = 27) 38.7 ± 7.2 (TT; n = 11) 0.62
rs2032582 (wildtype allele) 44.4 ± 7.1 (GG/GA/GT; n = 28) 39.7 ± 7.9 (AA/AT/TT; n = 10) 0.72
rs2235040 (variant allele) 23.87 ± 4.8 (GA/AA; n = 10) 50.0 ± 7.0 (GG; n = 28) <0.01
B. Mean baseline nondisplaceable binding potential by ABCB1 SNP allele carriershipa
SNP Carrier (genotype; n) Noncarrier (genotype; n) P valueb
rs1045642 (variant allele) 0.62 ± 0.04 (CT/TT; n = 25) 0.59 ± 0.05 (CC; n = 13) 0.70
rs1128503 (wildtype allele) 0.63 ± 0.04 (CC/CT; n = 27) 0.57 ± 0.05 (TT; n = 11) 0.47
rs2032582 (wildtype allele) 0.63 ± 0.04 (GG/GA/GT; n = 28) 0.57 ± 0.05 (AA/AT/TT; n = 10) 0.45
rs2235040 (variant allele) 0.67 ± 0.07 (GA/AA; n = 10) 0.59 ± 0.04 (GG; n = 28) 0.25
C. Mean SERT-occupancy (%) by ABCB1 SNP allele carriershipa
SNP Carrier (genotype; n) Noncarrier (genotype; n) P valueb
rs1045642 (variant allele) 74.8 ± 4.8 (CT/TT; n = 25) 69.6 ± 7.6 (CC; n = 13) 0.55
rs1128503 (wildtype allele) 77.1 ± 4.7 (CC/CT; n = 27) 63.1 ± 7.4 (TT; n = 11) 0.12
rs2032582 (wildtype allele) 77.6 ± 4.5 (GG/GA/GT; n = 28) 60.4 ± 7.6 (AA/AT/TT; n = 10) 0.06
rs2235040 (variant allele) 76.7 ± 6.0 (GA/AA; n = 10) 71.7 ± 5.1 (GG; n = 28) 0.60
PSC, paroxetine serum concentration; SERT, serotonin transporter; SNP, single nucleotide polymorphism; SPECT, single-photon emission computed tomography. 
aData are given as mean  ±  SEM.
bP values <0.05 are shown in bold.
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in the Caucasian sample; data not shown) and after strat-
ification for carriership as described above, we observed 
decreases in AIC when fitting two curves for rs2032582 
(AIC decrease 9.8) and rs1045642 (AIC decrease 6.3) 
and rs1128503 (AIC decrease 5.3), indicating improved 
fit of the models for these SNPs, but not for rs2235040 
(AIC increase 0.5; Supplemental Table 4, Supplemental 
Digital Content 1, http://links.lww.com/PG/A230), similar 
to our initial analyses.
Relationship between 17-item Hamilton Depression 
Rating Scale-score and ABCB1 genotype
No associations were found between the ABCB1 geno-
types or the rs1045642C-rs2032582G-rs1128503T-hap-
lotype and clinical response to six weeks of paroxetine 
treatment. Neither decrease in HDRS
17
-score (corrected 
for baseline HDRS
17
-score; all P ≥ 0.08, Supplemental 
Table 5, Supplemental Digital Content 1, http://links.
lww.com/PG/A230), nor the number of responders (≥50% 
decrease in HDRS
17
-score; all P ≥ 0.37; Supplemental 
Table 5, Supplemental Digital Content 1, http://links.
lww.com/PG/A230) showed significant associations in the 
regression models.
For analyses based on carriership, also neither decrease 
in HDRS
17
-score (corrected for baseline HDRS
17
-score; 
all P ≥ 0.13, Table 3), nor the number of responders (all 
P ≥ 0.34; Table 3) showed significant associations in any of 
the regression models for genotype, carrier or haplotype 
groups.
Exclusion of the five potentially nonadherent patients 
(one responder and four nonresponders) or the non-Cau-
casian patients in our separate sensitivity analyses did not 
change the results on baseline-adjusted HDRS
17
-score or 
response-rate for genotype, carrier or haplotype groups 
[all P ≥ 0.06 after exclusion of the potentially nonadher-
ent patients (n = 76) and all P ≥ 0.08 after exclusion of the 
non-Caucasian patients (n = 48); data not shown].
Fig. 1
Paroxetine serum concentration and SERT-occupancy by paroxetine, stratified by ABCB1 gene carriership of the mutant allele at rs1045642 and 
rs2235040 and carriership of the wildtype allele at rs1128503 and rs2032582. PSC and SERT-occupancy after 6 weeks of 20 mg/day parox-
etine (OCC
6 weeks
) stratified by ABCB1 gene carriership of the mutant allele at rs1045642 (CC n = 13/38, T-carrier n = 25/38; panel a), carrier-
ship of the wildtype allele at rs1128503 (C-carrier n = 27/38, TT n = 11/38; panel b), carriership of the wildtype allele at rs2032582 (G-carrier 
n = 28/38, AA/AT/TT n = 10/38; panel c) and carriership of the mutant allele at rs2235040 (GG n = 28/38, A-carrier n = 10/38; panel d). Equation 
fitted: OCC PSC
PSC6 weeks
=
+
a
b
*
( )
, in which a represents maximal SERT-occupancy in the model (OCC
max
) and b the PSC with 50% 
SERT-occupancy (EC
50
). The corresponding EC
50
 and E
max
 values for all models shown are reported in Supplemental Table 3, Supplemental 
Digital Content 1, http://links.lww.com/PG/A230. All fitted models were significant throughout all stratifications for carriership (all F
4,34 
> 90.4; all 
P < 0.0001). Models fit for two curves were improved relative to no stratification for rs1045642, rs1128503 and rs2032582 (AIC decrease for 
one fitted curve vs two fitted curves 0.2, 1.8 and 3.8, respectively) but not for rs2235040 (AIC increase 15.0). AIC, Akaike Information Criterion; 
PSC, paroxetine serum concentration; SERT, serotonin transporter.
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Data were not confounded by age, sex or PSC in any of 
the regression analyses, except for the sensitivity analy-
ses of response-rate for the Caucasian patients. Sex con-
founded the response-rate in this subgroup (P = 0.149 for 
the univariate model) and was therefore included in the 
regression models for response rate.
Discussion
In this study, we quantified that two of four previ-
ously studied ABCB1 gene polymorphisms (rs1128503, 
rs2032582) modify the association between PSC and 
SERT-occupancy in the midbrain (n = 38) but none of 
the four polymorphisms of interest were associated with 
clinical response after six weeks of paroxetine treatment 
(n = 81).
ABCB1 and serotonin transporter-occupancy
To the best of our knowledge, this is the first study to 
investigate whether the association between SSRI serum 
concentration and SERT-occupancy is modified by 
ABCB1 polymorphisms. We expected that ABCB1 pol-
ymorphisms associated with lower P-gp expression or 
activity or with higher response-rate or shorter time to 
remission or associated with more than one of these four 
phenotypic presentations, would also influence the non-
linear relationship between PSC and SERT-occupancy 
in the midbrain, with higher SERT-occupancy in these 
variant allele groups because of higher paroxetine con-
centrations at the target site (Ruhé et al., 2009a; Brambila-
Tapia, 2013). However, the evidence on the associations 
between ABCB1 polymorphisms and P-gp expression, 
activity or expected (in-vivo) effects is limited and 
mostly coming from in-vitro studies. The available litera-
ture is therefore insufficient to make definite statements 
about the expected effects in our study. Nevertheless, we 
summarize the available study results per SNP hereafter.
rs1045642
For rs1045642, we confirmed our hypothesis – after hav-
ing certified that the results were not due to mean dif-
ferences in SERT-occupancy between carriership groups. 
Our intention-to-treat analysis showed higher SERT 
occupancies at lower PSC for the rs1045642 TT geno-
type, which is in agreement with studies showing that 
this genotype is associated with decreased P-gp gene 
expression, decreased mRNA stability and a diminished 
function (Hitzl et al., 2001; Wang et al., 2005; Salama et 
al., 2006; Hemauer et al., 2010). However, after leaving 
out the potentially nonadherent patients, stratification 
for carriership of the variant T allele did not improve 
the model anymore. As this sensitivity analysis may bet-
ter reflect the relationship of PSC and SERT-occupancy, 
this result suggests that if rs1045642 modifies the PSC-
SERT-occupancy relationship, the effect may be small. 
This might be explained by the fact that it is a synony-
mous SNP, which does not alter the amino acid sequence 
of the P-gp protein.
rs1128503 and rs2032582
Stratification for carriership of the wildtype alleles for 
both rs1128503 and rs2032582 showed a significant mod-
ification of the PSC-SERT-occupancy curve without 
differences in PSC or SERT-occupancy between the car-
riership groups. However, higher SERT occupancies were 
found for carriers of the wildtype C-/G-alleles at all levels 
of PSC (Table 2b and Fig. 1b and c), while we expected 
the opposite from studies that reported decreased gene 
expression and diminished function with the rs1128503 
variant T-allele (Salama et al., 2006; Hemauer et al., 2010) 
and reduced protein expression and diminished function 
for the rs2032582 variant T(/A)-allele (Salama et al., 2006; 
Hemauer et al., 2010). One explanation for this coun-
ter-intuitive finding may be that the evidence for effects 
of these SNPs on P-gp expression and activity is limited, 
based on a few small studies while results are often con-
tradictory (Brambila-Tapia, 2013). Another explanation 
may be that the exact role of P-gp in paroxetine in general 
is not yet fully understood. Most studies agree on paroxe-
tine being a P-gp substrate, but paroxetine has also been 
identified as a weak inhibitor (Uhr et al., 2003; Mihaljevic 
Table 3 Clinical response after 6 weeks of paroxetine 20 mg/day 
stratified by permeability glycoprotein carriership at four single 
nucleotide polymorphisms (n = 81)
n Decrease in HDRS17-score
a P valueb
P-gp genotype rs1045642
 CC 22 5.9 ± 0.05 0.13
 T-carrier 59 8.4 ± 0.04
P-gp genotype rs1128503
 C-carrier 63 8.16 ± 0.03 0.28
 TT 18 6.3 ± 0.06
P-gp genotype rs2032582
 G-carrier 64 7.8 ± 0.02 0.83
 AA or AT or TT 17 7.5 ± 0.03
P-gp genotype rs2235040
 GG 63 8.3 ± 0.02 0.20
 A-carrier 18 5.9 ± 0.05
rs1045642 C -rs2032582 G- rs1128503 T-haplotype
 Absent 49 7.8 ± 0.00 0.72
 Present 32 7.4 ± 0.00
 n Number of respondersc P valued
P-gp genotype rs1045642
 CC 22 5 (22.7) 0.34
 T-carrier 59 20 (33.9)
P-gp genotype rs1128503
 C-carrier 63 20 (31.7) 0.75
 TT 18 5 (27.8)
P-gp genotype rs2032582
 G-carrier 64 20 (31.3) 0.88
 AA or AT or TT 17 5 (29.4)
P-gp genotype rs2235040
 GG 63 20 (31.7) 0.75
 A-carrier 18 5 (27.8)
rs1045642 C -rs2032582 G- rs1128503 T-haplotype
 Absent 49 16 (32.7) 0.67
 Present 32 9 (28.1)
HDRS
17
, Hamilton Depression Rating Scale; P-gp, permeability glycoprotein.
aData are given as mean decrease in HDRS
17
 after correction for baseline 
HDRS
17
-score  ±  SEM.
bFrom linear regression analysis.
cData are given as number of patients with ≥50% decrease in baseline HDRS
17
-
score (percentage).
dFrom logistic regression analysis.
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Peles et al., 2008; O’Brien et al., 2012) or even a (strong) 
inhibitor instead of a substrate (Weiss et al., 2003; Maines 
et al., 2005). However, if paroxetine is an inhibitor of the 
P-gp, our results may only be explained by increased 
function of P-gp with the variant T/A-alleles for these 
two SNPs or decreased P-gp function with the wildtype 
alleles. In the former case, the increased P-gp function 
would be at least partially undone by P-gp inhibition by 
paroxetine, while in the latter situation, P-gp inhibition 
leads to an even larger dysfunction of the P-gp-enzyme 
in wildtype carriers, both resulting in higher SERT-
occupancy for the G/C-carriers compared to the variant 
T/A-alleles. To confirm these possible explanations, P-gp 
expression/activity patterns and measurements of parox-
etine concentration within the brain would be necessary.
rs2235040
Only in our sensitivity analysis, rs2235040 was also asso-
ciated with a modified relationship between PSC and 
SERT-occupancy at the carriership level with – confirm-
ing our hypothesis – higher SERT occupancies for carri-
ers of the variant A-allele compared to the GG genotype. 
However, carriers of the variant A-allele had lower PSC 
than noncarriers in both our intention-to-treat and sensi-
tivity analysis (both P = 0.004). This may be the result of 
fewer subjects with the A-allele (Table 2), but limits the 
straightforward interpretation for this SNP. Replication 
of this study in a larger sample size is warranted to con-
firm whether the genotype at rs2235040 explains some 
of the variability in the relationship between PSC and 
SERT-occupancy.
ABCB1 and clinical response
rs1045642 and rs1128503
Our results showed no association with ABCB1 geno-
types at rs1045642 and rs1128503, in line with previous 
studies and two meta-analyses (Gex-Fabry et al., 2008; 
Kato et al., 2008; Mihaljevic Peles et al., 2008; Menu et 
al., 2010; Niitsu et al., 2013; Breitenstein et al., 2015). 
As for the variant T-allele of both SNPs inconsistent 
effects on P-gp gene and protein expression and activity 
were reported, our nonsignificant results may at best be 
indicative of a small, clinically irrelevant effect on P-gp 
activity (Brambila-Tapia, 2013). However, we think a rel-
evant association of these SNPs with clinical outcomes 
is unlikely since none of the individual studies using 
paroxetine included in the two meta-analyses found an 
effect of rs1045642 on response. Furthermore, our sen-
sitivity analyses of nonadherence also pointed to a lack 
of modification of the PSC-SERT-occupancy curves by 
these SNPs.
rs2032582
For rs2032582, our results are in agreement with most 
studies including a second meta-analysis by Breitenstein 
et al. (2015), showing that this SNP is not associated with 
clinical response (Gex-Fabry et al., 2008; Mihaljevic Peles 
et al., 2008; Kato et al., 2015;). Previous studies have found 
contradictory results on the effect of this polymorphism 
on P-gp expression and activity. In contrast to our SERT-
occupancy and response analyses, one meta-analysis by 
Niitsu et al. (2013) including 1252 subjects showed a weak 
evidence of worse response in the GG genotype group 
compared to the TT genotype [odds ratio (OR) = 0.75, 
95% confidence interval (CI) 0.58–0.97]. Although three 
of the four studies included in that meta-analysis focused 
on paroxetine, pooled efficacy stratified by ABCB1 geno-
type was only given for all antidepressants together, lim-
iting firm conclusions regarding paroxetine specifically. 
In the studies in patients using SSRI’s including par-
oxetine (n = 1176), the meta-analyzed remission rate for 
patients with GG genotype was worse than in patients 
with the TT genotype (OR = 0.70, 95% CI 048–0.98), 
which is in contrast with our SERT-occupancy results 
(Niitsu et al., 2013). However, we were unable to subdi-
vide the homozygous mutant group based on presence 
of A- or T-alleles (instead of the G allele) in our sample, 
and thus we were unable to replicate findings specifically 
related to the T-allele.
rs22305040
For rs22305040, no evidence is available on the effects of 
this polymorphism on P-gp expression or activity. While 
one study reported shorter time to remission during par-
oxetine treatment for geriatric depression in A-allele 
carriers for rs2235040, we found no association of the 
genotype for this SNP with response after six weeks of 
paroxetine treatment and neither did a recent meta-anal-
ysis of ABCB1 gene polymorphisms and antidepressant 
treatment (Sarginson et al., 2010; Breitenstein et al., 2015).
rs1045642C-rs2032582G-rs1128503T haplotype
The rs1045642C-rs2032582G-rs1128503T-haplotype 
has been shown to be associated with lower HDRS
21
-
change to paroxetine in 68 Japanese MDD-patients 
followed for six weeks (Kato et al., 2008). Although our 
SERT-occupancy results are suggestive of effects in this 
direction, we found no significant association with effi-
cacy. Comparison of our results with the Japanese sample 
might be complicated by potential effect modification by 
ethnicity, a known source of bias in (ABCB1) pharmacog-
enomics (Brambila-Tapia, 2013).
Strengths and limitations
Strengths of this study are the combination of variabil-
ity in the ABCB1 gene and a better quantifiable meas-
ure of the possible interacting effect of the genotypes, 
namely, SERT-occupancy. This is an innovative approach 
to investigate possible factors for personalizing medicine. 
Nevertheless, some limitations need to be considered 
when interpreting the results of this study. First, although 
the largest SPECT treatment study to date (Ruhé et al., 
2009a,b), only 38 patients were analyzed for the effects of 
genotype on SERT-occupancy. Despite the resulting low 
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power to find effects of genotypes, we found modification 
of the relationship between PSC and SERT occupancy 
for at least two ABCB1 polymorphisms. Nevertheless, 
replication of our findings in larger samples is warranted. 
Also, our analyses of treatment outcome with 81 partici-
pants are powered to distinguish effect sizes of 0.7 only. 
Therefore, our study might have resulted in nonsignifi-
cant findings for smaller effects for different genotypes 
instead of carriership. Moreover, our clinical results are 
skewed to non-responders, which we could partially 
address by using the continuous decrease in HDRS
17
-
score. Second, we used [123I]β-CIT for SPECT imaging, 
a nonselective radioligand that also binds to dopamine 
transporters (DATs; e.g., midbrain substantia nigra) 
and norepinephrine transporter (NET; e.g., locus coer-
uleus) (Neumeyer et al., 1991, 1996; Innis et al., 2007). 
Nevertheless, uptake in the midbrain is considered to 
reflect predominantly SERT, as this structure is relatively 
rich of SERT compared with DAT and NET (Laruelle 
et al., 1993). Moreover, we measured SERT-occupancy 
with SPECT four hours after injection of the radioligand. 
At that time point, the radioligand is at equilibrium for 
SERT binding, while the equilibrium for DAT binding 
is reached after 24 hours (Pirker et al., 2000). Therefore, 
we believe the change in [123I]β-CIT-binding in the 
midbrain reflects SERT-occupancy in particular (Ruhé 
et al., 2009a). Unfortunately, PET data on [11C]DASB 
SERT-occupancy after exposure to different SSRIs 
(Meyer et al., 2001, 2004) in combination with ABCB1 
polymorphisms are unavailable (J.H. Meyer, personal 
communication). Third, we measured SERT-occupancy 
in the midbrain as a proxy for SERT-occupancy in the 
cortex, where therapeutic effects occur. However, there 
are no SPECT ligands available to measure cortical 
SERT occupancy. Fourth, we previously demonstrated 
(in the present sample) that the 5-HTTLPR promoter 
polymorphism modified the association between SERT 
occupancy and clinical response: in the patients with the 
L
A
/L
A
 genotype higher SERT occupancy was associated 
with increased response on the Hamilton scale (Ruhé et 
al., 2009b). Although not our primary aim of investigation, 
due to our modest sample size, we could not investigate 
the combined effect of these two factors of clinical out-
come. In addition, although a different aim too, changing 
effects in combination with cytochrome P450 2D6 pol-
ymorphisms could not be examined. Fifth, our sample 
had no homogenous ethnicity (Table  1), which might 
have confounded our results. Therefore, we performed 
a sensitivity analysis in which we excluded all non-Cau-
casian patients; this did not change the results. Sixth, a 
recent study reported significant, ethnicity independ-
ent, associations of the rs10245483 G/G homozygotes 
with the SSRIs escitalopram and sertraline (Schatzberg 
et al., 2015), while in an elderly population (Sarginson et 
al., 2010), this SNP did not affect efficacy of paroxetine. 
As we choose our variants before this positive result was 
published, we did not determine the same SNPs in our 
analysis. Seventh, although blocking SERT is consid-
ered the mechanism of action of SSRIs, an easier expla-
nation for the absence of a significant relationship with 
response might be that the direct relationship between 
SERT-occupancy and response to paroxetine treatment 
is at least questionable (Ruhé et al., 2009a). This suggests 
that our findings of modified PSC-SERT-occupancy rela-
tionships by P-gp polymorphisms are the most important 
points of the present study, indicating modified intrac-
erebral pharmacokinetics due to P-gp polymorphisms. 
Because response to SSRI will presumably not be deter-
mined by SERT-occupancy only, it is possible that the 
different SERT-occupancies by the SNPs under study 
may be a contributing factor to final response and must 
be investigated in combination with other factors. Given 
our sample size, this was not possible in our modest study 
population, which warrants further research. Finally, we 
only addressed four (well studied) SNPs of the ABCB1 
gene. In addition, we only considered therapeutic effects 
of paroxetine, while the influence on side effects could be 
interesting as well (Bet et al., 2016). A genome wide asso-
ciation study, for example, would provide more insight 
in other ABCB1 gene SNPs potentially associated with 
effects and side effects of paroxetine or SSRI treatment 
in general. This information is additionally required.
Conclusion
We found evidence that at least two previously studied 
ABCB1 gene polymorphisms (rs1128503 and rs2032582) 
are associated with a modified relationship between PSC 
and SERT-occupancy in the midbrain. As such, phar-
macokinetic influences of the ABCB1 polymorphisms 
rs1128503 and rs2032582 might have a potentially rele-
vant pharmacogenetic effect in SSRI efficacy, although 
those are not likely to be the only factor. However, none of 
the four studied SNPs nor the rs1045642C-rs2032582G-
rs1128503T-haplotype were significantly associated with 
clinical response after six weeks of paroxetine treatment, 
but power to detect differences in efficacy was low with 
our moderate sample size. Future studies are needed to 
support the role of ABCB1 genotyping to aid in individu-
alizing SSRI pharmacotherapy.
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